JP7531404B2 - 癌の処置 - Google Patents

癌の処置 Download PDF

Info

Publication number
JP7531404B2
JP7531404B2 JP2020563542A JP2020563542A JP7531404B2 JP 7531404 B2 JP7531404 B2 JP 7531404B2 JP 2020563542 A JP2020563542 A JP 2020563542A JP 2020563542 A JP2020563542 A JP 2020563542A JP 7531404 B2 JP7531404 B2 JP 7531404B2
Authority
JP
Japan
Prior art keywords
nkg2a
antibody
tumor
individual
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523170A (ja
JP2021523170A5 (OSRAM
Inventor
アブドラ，シャード，エッサ
グプタ，アショク，クマール
ソン，シューヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2021523170A publication Critical patent/JP2021523170A/ja
Publication of JP2021523170A5 publication Critical patent/JP2021523170A5/ja
Priority to JP2024059910A priority Critical patent/JP2024102055A/ja
Application granted granted Critical
Publication of JP7531404B2 publication Critical patent/JP7531404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020563542A 2018-05-15 2019-05-14 癌の処置 Active JP7531404B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024059910A JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
US62/671,521 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024059910A Division JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Publications (3)

Publication Number Publication Date
JP2021523170A JP2021523170A (ja) 2021-09-02
JP2021523170A5 JP2021523170A5 (OSRAM) 2022-05-26
JP7531404B2 true JP7531404B2 (ja) 2024-08-09

Family

ID=66752041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563542A Active JP7531404B2 (ja) 2018-05-15 2019-05-14 癌の処置
JP2024059910A Pending JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024059910A Pending JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Country Status (13)

Country Link
US (1) US12209126B2 (OSRAM)
EP (1) EP3793607A1 (OSRAM)
JP (2) JP7531404B2 (OSRAM)
KR (1) KR102885515B1 (OSRAM)
CN (1) CN112203691A (OSRAM)
AU (2) AU2019270277B9 (OSRAM)
CA (1) CA3099820A1 (OSRAM)
EA (1) EA202092696A1 (OSRAM)
IL (1) IL278618B2 (OSRAM)
MA (1) MA52627A (OSRAM)
SG (1) SG11202011117VA (OSRAM)
TW (1) TW202011989A (OSRAM)
WO (1) WO2019219658A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
IL297412A (en) * 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
US20230183296A1 (en) * 2020-05-13 2023-06-15 Nanjing Legend Biotech Co., Ltd. Compositions and methods for reducing host rejection of allogeneic cells using simian icp47 and variants thereof
CN117730094A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
KR20240067131A (ko) * 2021-10-04 2024-05-16 르 라보레또레 쎄르비에르 Nkg2a를 표적화하는 암 요법
WO2023114176A2 (en) * 2021-12-14 2023-06-22 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to cd94/nkg2a heterodimer polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (OSRAM) 2009-11-24 2018-01-06
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
RU2017105425A (ru) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3193931B1 (en) 2014-09-16 2020-08-05 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR102598068B1 (ko) 2014-10-23 2023-11-06 이나뜨 파르마 에스.에이. 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
WO2019219658A1 (en) 2019-11-21
AU2025200275A1 (en) 2025-01-30
IL278618B2 (en) 2025-11-01
EP3793607A1 (en) 2021-03-24
JP2024102055A (ja) 2024-07-30
SG11202011117VA (en) 2020-12-30
JP2021523170A (ja) 2021-09-02
CN112203691A (zh) 2021-01-08
AU2019270277B9 (en) 2024-12-05
AU2019270277B2 (en) 2024-11-21
US20210253694A1 (en) 2021-08-19
IL278618A (OSRAM) 2021-01-31
US12209126B2 (en) 2025-01-28
AU2019270277A1 (en) 2021-01-07
TW202011989A (zh) 2020-04-01
CA3099820A1 (en) 2019-11-21
KR102885515B1 (ko) 2025-11-12
EA202092696A1 (ru) 2021-04-05
KR20210010486A (ko) 2021-01-27
IL278618B1 (en) 2025-07-01
MA52627A (fr) 2021-03-24

Similar Documents

Publication Publication Date Title
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
JP7531667B2 (ja) リンパ球における阻害経路の中和
US12209126B2 (en) Treatment of cancer
CN112004828B (zh) 头颈癌的治疗
EA049949B1 (ru) Лечение рака
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240730

R150 Certificate of patent or registration of utility model

Ref document number: 7531404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150